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Abstract
Background: A meta-analysis was performed to evaluate the use of clinical pathways for hip and knee joint
replacements when compared with standard medical care. The impact of clinical pathways was evaluated assessing
the major outcomes of in-hospital hip and knee joint replacement processes: postoperative complications,
number of patients discharged at home, length of in-hospital stay and direct costs.
Methods: Medline, Cinahl, Embase and the Cochrane Central Register of Controlled Trials were searched. The
search was performed from 1975 to 2007. Each study was assessed independently by two reviewers. The
assessment of methodological quality of the included studies was based on the Jadad methodological approach
and on the New Castle Ottawa Scale. Data analysis abided by the guidelines set out by The Cochrane
Collaboration regarding statistical methods. Meta-analyses were performed using RevMan software, version 4.2.
Results: Twenty-two studies met the study inclusion criteria and were included in the meta-analysis for a total
sample of 6,316 patients. The aggregate overall results showed significantly fewer patients suffering postoperative
complications in the clinical pathways group when compared with the standard care group. A shorter length of
stay in the clinical pathway group was also observed and lower costs during hospital stay were associated with
the use of the clinical pathways. No significant differences were found in the rates of discharge to home.
Conclusion: The results of this meta-analysis show that clinical pathways can significantly improve the quality of
care even if it is not possible to conclude that the implementation of clinical pathways is a cost-effective process,
because none of the included studies analysed the cost of the development and implementation of the pathways.
Based on the results we assume that pathways have impact on the organisation of care if the care process is
structured in a standardised way, teams critically analyse the actual organisation of the process and the
multidisciplinary team is highly involved in the re-organisation. Further studies should focus on the evaluation of
pathways as complex interventions to help to understand which mechanisms within the clinical pathways can
really improve the quality of care. With the need for knee and hip joint replacement on the rise, the use of clinical
pathways might contribute to better quality of care and cost-effectiveness.
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Background
The use of hip and knee joint replacement (JR) has been
steadily increasing during the last few years [1]. It is also
expected that the pressure for use of JR will further
increase in healthcare systems worldwide because of the
ageing population and the related increased prevalence of
osteoarthritis [2,3]. Although JR is a cost-effective treat-
ment both from the clinical and patients' perspective, JR
represents a significant cost to hospitals due to the contin-
uous advances in prosthetic design and materials. This
could be a critical issue in healthcare systems because of
the decline in available funds for public healthcare
[1,4,5]. As a result, from a public health perspective,
adjustments in the care process are necessary for cost con-
tainment without compromising the quality of patient
care [6].
Several methodologies to reduce the costs and to improve
the management of these patients have been advocated. A
major organisational strategy is a clinical pathway [7-12].
Clinical pathways, also known as care pathways or critical
pathways, are a methodology for the mutual decision
making and organisation of care for a well-defined group
of patients during a well-defined period [7,10,13-15].
Although clinical pathways have been used since the
1980s, there is increasing debate about what they are and
how they affect patients' care and outcomes. As a conse-
quence their use in healthcare systems in high volume and
costly care like JR is still jeopardised and evidence is
needed to support public health decision makers in
understanding the real impact of this methodology
[9,10,15-20].
Therefore, this meta-analysis was performed to evaluate
the use of JR clinical pathways when compared with
standard medical care. Based on a previous review the
impact of clinical pathways was evaluated assessing the
major outcomes of in-hospital JR processes: postoperative
complications, number of patients discharged at home,
length of in-hospital stay (LOS) and direct costs [9].
Methods
Literature search
Medline, Cinahl, Embase and the Cochrane Central Reg-
ister of Controlled Trials were searched using the follow-
ing medical subject headings (MeSH) related to clinical
pathways and joint replacement: critical pathways AND
arthroplasty, replacement, hip AND arthroplasty, replace-
ment, knee AND joint prosthesis. Secondly, a non-MeSH
search was performed, based on the following search
string: ('clinical pathway' OR 'critical pathway' OR 'care
map' OR 'clinical path' OR 'multidisciplinary approach')
AND (arthroplasty OR replacement OR prosthesis OR
joint OR knee OR hip). The search was limited to articles
published between 1975 and 2007, because the first clin-
ical pathways in healthcare originated in the 1980s [21].
No language restrictions were used. The details are
reported in the methods for identification of studies in the
search strategy file (Additional file 1). The authors of rele-
vant studies were contacted for further information. One
author replied that the data was not available [22]. Three
authors provided the original data [6,10,11]. The other
authors did not reply. The review protocol was not pub-
lished prior to the study.
Study inclusion/exclusion criteria
Randomised controlled trials (RCT), controlled clinical
trials (CCT, including pseudo-randomised and controlled
before-after designs), interrupted time series, cohort and
case-control studies were included in the meta-analysis.
Studies were considered randomised when it was specifi-
cally stated in the text, although the method of randomi-
sation was not always adequately described. Trials were
defined as pseudo-randomised when individuals were
assigned to alternative forms of treatment using quasi-ran-
domised methods of allocation such as alternation, date
of birth or case record numbers. All the included studies
compared the care provided through the clinical pathways
with standard medical care. Studies were included when
at least one of the following outcome indicators have
been evaluated: frequency of postoperative complications
(complications were defined as factors affecting recovery
that required re-admission or prolonged hospital stay
such as wound infections, chest infections, pulmonary
oedema, deep vein thrombosis, joint dislocation and
manipulation, pressure ulcers and urinary tract infec-
tions), frequency of patients discharged at home
(expressed as a rate), LOS (defined as the number of days
of hospitalisation from admission/surgery to discharge
from the acute hospital; the Weighted Mean Difference
(WMD) of the LOS was used in the study as a synthetic
measure of the LOS differences observed in the two
groups) and direct costs (referred to total cost of acute
hospitalisation such as operating room, patient care unit,
medications and supplies: in order to compare clinical
pathways with usual care the costs were measured in
United States dollars (US$) divided by 10,000 and
expressed as WMD). One of eight of the included studies
did not report the costs in US$ [23]. Therefore its costs
were converted using the official exchange rate of the year
of the study (year 1998). The costs were adjusted accord-
ing to the United States inflation rate of the period of the
studies (years 1995 to 2000) and the costs were actualised
to year 2000 (mean inflation rate = 2.8% per year). Arti-
cles that were strictly descriptive (review articles, historical
and theoretical articles), articles with no control group,
articles that did not assess at least one of the four out-
comes and non-specific articles (for example, JR in hip
fracture, JR in femoral neck fracture) were excluded. For
continuous variables, since means are influenced by
extremes of values, the studies that did not report theBMC Medicine 2009, 7:32 http://www.biomedcentral.com/1741-7015/7/32
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standard deviations were also excluded from this meta-
analysis [16].
Outcome measures
The purpose of this research was to combine the results of
the published studies on clinical pathways for JR in order
to have a total vision of the effects of their implementa-
tion. Because clinical pathways are a complex intervention
to keep the structure, the multidisciplinary team process
and the follow-up of the outcomes of a specific care proc-
ess alive, the results of the meta-analysis were based on
the four outcome measures that have been described
before (postoperative complications, discharge to home,
LOS and costs) [15]. According to the literature the chosen
outcomes were potentially the more suitable measures to
describe the effect of the clinical pathways for JR among
the endpoints available in the included studies.
Data extraction and quality assessment
The author, the publication year and country, the sample
size, the characteristics of the population studied (age,
sex, race, primary diagnosis, ASA score, Charlson score,
pain score, operation type, etc.), study design, type of con-
trol and outcome measures were recorded [24,25]. Each
study was assessed independently by one Italian and one
Belgian reviewer. Two reviewers screened all the titles,
abstracts and keywords of publications identified by the
searches to assess their eligibility. The reviewers were
blinded to the names of the authors, institution where the
work had been carried out, and the journal. Two reviewers
independently assessed the methodological quality of all
the included studies and recorded the findings.
Discrepancies between reviewers' assessments of the pub-
lications, conceptual problems on the pathway interven-
tion or methodological and statistical problems were
solved through discussion with the overall research team.
The overall international research team included ortho-
paedic surgeons, public health specialists, clinical path-
way experts, biostatisticians and experts in research
methodologies. The assessment of methodological qual-
ity of the included studies was based on the Jadad meth-
odological approach for RCT and CCT and the New Castle
Ottawa Scale for the case-control studies, cohort studies
and time interrupted series [26,27]. The Jadad approach is
a five-point scale that assigns points to each study on the
basis of the quality of the randomisation generation (0–2
points), of the blinding process (0–2 points) and of the
description of withdrawals and dropouts (0–1 point). In
general a total score of 3 or more points is achieved only
by high quality studies. The New Castle Ottawa Scale is a
nine-point scale that assigns points on the basis of the
process of selection of the cohorts or of the case and of the
controls (0–4 points), of the comparability of the cohorts
or of the case and of the controls (0–2 points), and of the
identification of the exposure and of the outcomes of
study participants (0–3 points). All the studies that met
the inclusion criteria (see above) but did not get any
points from the assessment of the methodological quality
were excluded.
Data analysis
Data analysis abided by the guidelines set out by The
Cochrane Collaboration regarding statistical methods
[28]. For dichotomous variables, the relative treatment
effect was expressed as relative risk with 95% confidence
levels (95%CI). For the meta-analysis of continuous vari-
ables, the WMD with 95%CI was used. The weighting pro-
cedure took the within study variance around the mean
into account to calculate the studies' contribution to the
overall results. Since means are influenced by extreme of
values, this analysis could use the means only if the stand-
ard deviations were also provided. A P-value < 0.05 was
used as the significance threshold. Statistical heterogene-
ity of the data was quantified using the I2 statistic [29]. For
all the outcomes the 'random effects' method was used,
based upon intention to treat data from individual stud-
ies. The results for each measure outcome were presented
separately for randomised and non-randomised studies.
The results were represented with the Forest plot, which
showed the strength of the evidence: in the plot the left-
hand column listed the names of the studies, the right-
hand column showed the measure of effect (expressed as
odds ratios with 95%CI). According to the test the overall
meta-analyses were considered to not have any significant
effects at the given level of confidence when the overall
diamonds overlapped the line of no-effect results. Poten-
tial publication bias was assessed using funnel plots. A
funnel plot is a scatterplot of the treatment effects esti-
mated from individual studies (horizontal axis) against a
measure of study size (vertical axis). Treatment effects
were expressed as risk ratio (RR) or weighted mean differ-
ence. Measure of study size was expressed as the reciprocal
of studies' standard error [30]. All meta-analyses were per-
formed using RevMan software, version 4.2 [31].
Results
Description of the studies
The search strategy found a total of 479 records, but only
20 were articles published between 1975 and 2007 and
which met the study inclusion criteria; these were
included in the meta-analysis for a total sample of 6,316
patients, as shown in Figure 1[6,10,11,22,23,32-46]. The
papers of Brunenberg et al. [6] and Macario et al. [37]
reported the results of applying clinical pathways on two
cohorts of patients, divided by hip and knee arthroplasty.
Because of this we included in the meta-analysis the four
studies separately and we coded them as 'Brunenberg
Hip', 'Brunenberg Knee', 'Macario Hip' and 'Macario
Knee'. So a total of 22 studies, out of the 20 publicationsBMC Medicine 2009, 7:32 http://www.biomedcentral.com/1741-7015/7/32
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selected, were available for the meta-analysis. Two publi-
cations reported results of multi-centre design whereas
twenty were single-centre studies [see Additional file 2]. In
detail the study designs included one RCT [32], one inter-
rupted time series [11] and twenty cohort studies
[6,10,22,23,33-46]. Twelve of the twenty-two studies con-
cerned a knee arthroplasty patient group, six a hip arthro-
plasty patient group and four both. Thirteen studies were
based in the United States, two in Australia, one in Bel-
gium, one in Italy, two in The Netherlands, one in New
Zealand, one in Spain and one in Taiwan. The setting
characteristics of the studies (that is, hospital size and
urban/rural typology, education, living situation) were
not fully reported.
Effect of clinical pathways: postoperative complications
In Figure 2 the results concerning the effect of the imple-
mentation of clinical pathways on the incidence of post-
operative complications are reported (deep venous
thrombosis, pulmonary embolism, manipulation, super-
ficial infection, deep infection, heel decubitus). The aggre-
gate overall results showed significantly fewer patients
suffering postoperative complications in the clinical path-
ways group when compared with the standard care group
(RR = 0.68, 95%CI = 0.51–0.92, P = 0.01; I2 = 47.2 P =
0.04). The funnel plot showed a relatively symmetric dis-
tribution but not a distinctive funnel form (Figure 3). In
detail, in the 10 cohort studies [22,33,34,36,38,40-43,45]
that included a total sample of 2,872 patients, a signifi-
cant trend toward fewer postoperative complications in
the clinical pathway group has been shown (RR = 0.73,
95%CI = 0.53–0.99, P = 0.05). A significant reduction in
complication rates in the clinical pathway group was also
shown in the randomised trial by Dowsey et al. [32],
which included 163 patients (RR = 0.39, 95%CI = 0.19–
0.77, P = 0.007).
Effect of clinical pathways: discharge to home
As shown in Figure 4, the seven cohort studies [33-36,44-
46], which included 2,107 patients, did not report any sig-
nificant differences in ratios of discharge to home (RR =
0.77, 95%CI = 0.54–1.10, P  = 0.15; I2 = 91.8%, P  <
0.00001). The funnel plot is shown in Figure 5.
Effect of clinical pathways: LOS
LOS was used as an indicator in 13 studies (aggregated
total study sample of 2,553 patients) [6,10,11,23,35-
37,39,41,44,45]. As shown in Figure 6, a significantly
shorter LOS in the clinical pathway group was observed
both in the results of the cohort study designs (WMD = -
Flowchart of the selection of the studies Figure 1
Flowchart of the selection of the studies.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
479 publications
identified
323 publications excluded
(duplicated*)
156 publications
selected
136 publications excluded:
a. Descriptive studies (87)
review articles (9)
historical and theoretical articles (78)
b. Articles without control group (3)
c. Not specific articles (39)
d. Articles without standard deviation (7)
20 publications included:
•Randomised clinical trial (1)
•Time interrupted series (1)
•Cohort studies (20)BMC Medicine 2009, 7:32 http://www.biomedcentral.com/1741-7015/7/32
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2.67, 95%CI = (-)3.40–(-)1.94 days, P < 0.00001) and of
the interrupted time series design [11] (WMD = (-)2.24,
95%CI = (-)3.77–(-)0.70 days; P = 0.004). So the overall
results showed a significantly shorter LOS for the clinical
pathways group when compared with usual care (WMD =
-2.61, 95%CI = (-)3.29–(-)1.94 days, P < 0.00001; I2 =
90,9%, P < 0.00001). The funnel plot is shown in Figure 7.
The studies that did not report the standard deviation
[22,32-34,38,40,42,43,46] found a shorter LOS in the
clinical pathway group compared with the standard care
group (overall mean LOS of 479 days vs. 666 days) and in
seven studies [22,32-34,38,40,43] the reported differ-
ences were strongly significant (P < 0.01).
Effect of clinical pathways: hospitalisation costs
The costs during hospitalisation were analysed in eight
cohort studies, including an overall sample of 934
patients. These studies [6,23,36,37,45] showed significant
differences in hospitalisation costs when comparing the
clinical pathways with non-pathway based care. In partic-
ular, lower costs during hospital stay were associated with
the use of the clinical pathways, as shown in Figure 8
(WMD = (-)1.54, 95%CI = (-)1.99–(-)1.09, P < 0.00001;
I2 = 97,4%, P < 0.00001). The relative funnel plot is shown
in Figure 9.
Also, in the studies in which the standard deviations were
not reported [22,33,34,42] lower mean hospitalisation
costs were observed in the clinical pathway group
(US$19.401 vs. US$22.891) and in three [22,33,34] stud-
ies the observed differences were statistically significant.
Discussion
The main finding that emerged from this meta-analysis is
that clinical pathways can effectively improve the quality
of the care provided to the patients undergoing JR. The
clinical pathways improved the analysed range of selected
outcomes (LOS, postoperative complications, discharge
to home, hospitalisation cost). We would suggest that this
was due to the standardisation of the process of care, even
if the knowledge about the mechanisms through which
pathways work is insufficient and the evidence deter-
mined by meta-analysis is always exploratory in nature
and should be considered with caution [47].
A strongly significant reduction in the LOS after imple-
mentation of the clinical pathway was observed, and even
if it can be argued that a general trend towards a continu-
ous reduction of LOS has been existing in actual systems
of care (from 1993 to 1999, the mean hospital stay in
acute setting/wards for ankle JR dropped from 6.3 to 4.2
days) [48], this was not observed in the control group.
Meta-analysis of studies evaluating the effect of clinical pathways and standard care on postoperative complications Figure 2
Meta-analysis of studies evaluating the effect of clinical pathways and standard care on postoperative compli-
cations.
Review : Clinical pathway and total hip and knee arthroplasty
Comparison: 02 Care Pathway vs standard care                                                                              
Outcome: 01 Postoperative complications                                                                                
Study Care pathway  Standard care RR (random) Weight  RR (random)
or sub-category  n/N  n/N 95% CI %  95% CI
01 Cohort studies
 Mauerhan D                 23/591              1/191       2.08     7.43 [1.01, 54.68]      
 Healy W                     4/103              2/56        2.87     1.09 [0.21, 5.75]       
 Ho D                        5/60               2/30        3.15     1.25 [0.26, 6.07]       
 Wammack L (H)               4/31               5/24        4.96     0.62 [0.19, 2.06]       
 Teeny                       6/55               5/55        5.49     1.20 [0.39, 3.70]       
 Scranton P                 12/77              12/52       10.07     0.68 [0.33, 1.39]       
 Mabrey JD                   8/24              10/11       12.27     0.37 [0.20, 0.67]       
 Pearson S                  30/119             15/58       13.54     0.97 [0.57, 1.66]       
 Fisher                     34/553             41/340      15.83     0.51 [0.33, 0.79]       
 Pennington JM              67/261             59/181      19.26     0.79 [0.59, 1.06]       
Subtotal (95% CI) 1874               99 89.51     0.73 [0.53, 0.99
Total events: 193 (Care pathway), 152 (Standard care)
Test for heterogeneity: Chi² = 16.37, df = 9 (P = 0.06), I² = 45.0%
Test for overall effect: Z = 2.00 (P = 0.05)
02 RCT
 Dowsey M                   10/92              20/71       10.49     0.39 [0.19, 0.77]       
Subtotal (95% CI) 92                 7 10.49     0.39 [0.19, 0.77
Total events: 10 (Care pathway), 20 (Standard care)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.007)
Total (95% CI) 1966               106 100.00     0.68 [0.51, 0.92
Total events: 203 (Care pathway), 172 (Standard care)
Test for heterogeneity: Chi² = 18.95, df = 10 (P = 0.04), I² = 47.2%
Test for overall effect: Z = 2.48 (P = 0.01)
0.1 0.2 0.5 1 2 5 10
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Funnel plot analyses (postoperative complications) Figure 3
Funnel plot analyses (postoperative complications).
Review: Clinical pathw ay and total hip and knee arthroplasty
Comparison: 02 Care Pathway vs standard care                                                                              
Outcome: 01 Postoperative complications                                                                                
 0.1  0.2 0.5 1 2 5 10
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Meta-analysis of studies evaluating the effect of clinical pathways and standard care on discharge-to-home rates Figure 4
Meta-analysis of studies evaluating the effect of clinical pathways and standard care on discharge-to-home 
rates.
Review : Clinical pathway and total hip and knee arthroplasty
Comparison: 04 Care Pathway vs standard care                                                                              
Outcome: 01 Discharge to home                                                                                          
Study Care pathway  Standard care RR (random) Weight  RR (random)
or sub-category  n/N  n/N 95% CI %  95% CI
01 Cohort studies
 Healy W                     1/103             34/56        2.83     0.02 [0.00, 0.11]       
 Ireson                      7/64              11/64        8.84     0.64 [0.26, 1.54]       
 Mabrey JD                  15/24              11/11       16.48     0.65 [0.47, 0.90]       
 Fisher                     78/553             82/340      17.15     0.58 [0.44, 0.77]       
 Woo                        37/37              21/30       17.66     1.42 [1.12, 1.80]       
 Wammack L (H)              25/31              24/24       18.23     0.81 [0.68, 0.98]       
 Walter FL                 323/455            186/315      18.81     1.20 [1.08, 1.34]       
Subtotal (95% CI) 1267               84 100.00     0.77 [0.54, 1.10
Total events: 486 (Care pathway), 369 (Standard care)
Test for heterogeneity: Chi² = 72.94, df = 6 (P < 0.00001), I² = 91.8%
Test for overall effect: Z = 1.43 (P = 0.15)
Total (95% CI) 1267               84 100.00     0.77 [0.54, 1.10
Total events: 486 (Care pathway), 369 (Standard care)
Test for heterogeneity: Chi² = 72.94, df = 6 (P < 0.00001), I² = 91.8%
Test for overall effect: Z = 1.43 (P = 0.15)
0.1 0.2 0.5 1 2 5 10
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Funnel plot analyses (discharge to home) Figure 5
Funnel plot analyses (discharge to home).
Review: Clinical pathway and total hip and knee arthroplasty
Comparison: 04 Care Pathway vs standard care                                                                              
Outcome: 01 Discharge to home                                                                                          
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Meta-analysis of studies evaluating the effect of clinical pathways and standard care on LOS Figure 6
Meta-analysis of studies evaluating the effect of clinical pathways and standard care on LOS.
Review: Clinical pathway and total hip and knee arthroplasty
Comparison: 01 Care Pathway vs standard care                                                                              
Outcome: 03 Lenght of hospital stay                                                                                    
Study  Care pathway  Standard care  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 Cohort studies
Mabrey JD     24      4.70(1.40)          11     10.90(5.40)   3.02     -6.20 [-9.44, -2.96]      
Brunenberg (h)     48      5.96(8.30)          50      9.44(2.70)   4.29     -3.48 [-5.94, -1.02]      
Munoz     74     10.12(3.18)          98     19.41(11.78)   4.33     -9.29 [-11.73, -6.85]     
Wammack L (H)     31      5.00(1.60)          24      9.30(5.80)   4.44     -4.30 [-6.69, -1.91]      
Brunenberg (k)     30      4.87(3.10)          32     11.75(3.70)   6.14     -6.88 [-8.58, -5.18]      
Lin YK     69      9.10(1.90)          53     11.90(2.60)   8.72     -2.80 [-3.63, -1.97]      
Pennington JM    261     10.30(3.40)         181     12.90(4.70)   8.81     -2.60 [-3.40, -1.80]      
Ireson     64      6.69(2.10)          64      8.14(2.10)   9.00     -1.45 [-2.18, -0.72]      
Macario H    107      5.93(1.50)         144      7.15(2.86)   9.43     -1.22 [-1.77, -0.67]      
Panella M     57     12.81(1.04)          43     13.07(1.55)   9.46     -0.26 [-0.80, 0.28]       
Macario K     63      5.65(0.91)         120      6.66(1.68)   9.75     -1.01 [-1.39, -0.63]      
Walter FL    455      3.20(1.23)         315      4.50(1.74)   9.95     -1.30 [-1.52, -1.08]      
Subtotal (95% CI)   1283                        1135  87.36     -2.67 [-3.40, -1.94]
Test for heterogeneity: Chi² = 139.28, df = 11 (P < 0.00001), I² = 92.1%
Test for overall effect: Z = 7.19 (P < 0.00001)
02 Time interrupted series
Vanhaecht K First     32     12.10(3.56)          26     15.30(3.93)   5.46     -3.20 [-5.15, -1.25]      
Vanhaecht K Second     45     10.50(1.83)          32     12.10(3.56)   7.18     -1.60 [-2.94, -0.26]      
Subtotal (95% CI)     77                          58  12.64     -2.24 [-3.77, -0.70]
Test for heterogeneity: Chi² = 1.75, df = 1 (P = 0.19), I² = 42.9%
Test for overall effect: Z = 2.86 (P = 0.004)
Total (95% CI)   1360                        1193 100.00     -2.61 [-3.29, -1.94]
Test for heterogeneity: Chi² = 142.69, df = 13 (P < 0.00001), I² = 90.9%
Test for overall effect: Z = 7.60 (P < 0.00001)
 -10  -5  0  5  10
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Most of the cohort studies used historical control groups
(and therefore potentially susceptible to the bias due to
trends in LOS) many authors enrolled consecutive cases in
the control groups and this reduced the risk that some
cases were missed or excluded, which may have influ-
enced the outcome. Moreover, clinical pathways showed
their positive impact on LOS also when applied to other
conditions; therefore it is reasonable to think that the
reduction of LOS in JR was a consequence of the better
organisation of the care when implementing clinical path-
ways [10,12,18].
The positive effect of clinical pathways on the organisa-
tion of the care was also observed in the other measured
outcomes. A possible adverse consequence of an over-
stretched reduction in LOS could have been an increased
rate of postoperative complications, because of the reduc-
tion of the level of care. The opposite was found in this
meta-analysis. The use of clinical pathways significantly
decreased the number of postoperative complications,
and this was observed for all the complications including
deep venous thrombosis, pulmonary embolism, manipu-
lation, superficial and deep infections and heel decubitus,
therefore it is possible to conclude that both reduction of
LOS and clinical outcome improvements can be attrib-
uted to a better organisation of care.
This can also explain the observed reduction in costs while
using clinical pathways. An inappropriate process of care
can lead to negative clinical outcomes and to a long LOS.
Funnel plot analyses (LOS) Figure 7
Funnel plot analyses (LOS).
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Review: Clinical pathway and total hip and knee arthroplasty
Comparison: 05 Care Pathway vs standard care                                                                              
Outcome: 06 Hospitalisation cost                                                                                       
Study  Care pathway  Standard care  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Wammack L (H)     31      5.27(1.16)          24     10.90(4.28)   4.73     -5.63 [-7.39, -3.87]      
Mabrey JD     24      4.07(1.63)          11      5.86(1.71)   7.68     -1.79 [-2.99, -0.59]      
Macario H     63      6.91(2.51)         120     10.14(3.21)  10.60     -3.23 [-4.07, -2.39]      
Macario K    107      7.74(1.38)         144     12.22(3.36)  12.92     -4.48 [-5.09, -3.87]      
Ireson     64      6.47(1.25)          64      6.91(1.58)  14.04     -0.44 [-0.93, 0.05]       
Brunenberg (k)     30      0.28(0.37)          32      0.60(0.18)  16.57     -0.32 [-0.47, -0.17]      
Brunenberg (h)     48      0.34(0.47)          50      0.52(0.13)  16.60     -0.18 [-0.32, -0.04]      
Lin YK     69      0.76(0.03)          53      1.16(0.04)  16.86     -0.40 [-0.41, -0.39]      
Total (95% CI)    436                         498 100.00     -1.54 [-1.99, -1.09]
Test for heterogeneity: Chi² = 266.14, df = 7 (P < 0.00001), I² = 97.4%
Test for overall effect: Z = 6.67 (P < 0.00001)
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This was avoided in the hospitals using clinical pathways.
Unfortunately the majority of the studies included in this
meta-analysis reported a reduction of hospitalisation
costs without specifying the single costs of the specific ele-
ments of the process of care, so it is not possible to con-
clude that the reduction of the costs was achieved by a
more appropriate process of care or simply by a generic
reduction of the stay. The rate of patients discharged to
home was not significantly increased by the use of clinical
pathways and this is a possible weakness of the findings.
This meta-analysis has some further limitations. Most of
the reviewed studies were performed in academic hospi-
tals and some studies used small sample sizes, therefore a
patient selection could have occurred. This could reduce
the generalisation of the results but not their strength
because patients included in the clinical pathways group
did not differ from the patients treated with usual care in
age, sex and clinical co-morbidities. Moreover, from a
methodological perspective, when evaluating aggregate
results, it is easy to forget that most of the included studies
were not randomised trials [49]. Despite this, if only one
RCT was included in the meta-analysis, the analysed
cohort studies showed high quality scores and this helped
to ensure the internal validity of the research. The majority
of the included studies were performed at single sites, so
therefore the same staff could have treated both cases and
controls with a possible contamination bias. Adopting
part of the pathways in usual care if pathways are effective
could simply lead to a reduction of the effects of pathways
that in this study remain strongly significant.
As has been reported, the funnel plots showed a relatively
symmetric distribution, but the point cloud did not have
a distinctive funnel form. This was probably due to the rel-
atively high heterogeneity and to the small number of the
primary studies included in the meta-analysis. Therefore a
publication bias may have also occurred. This risk is
implicit in all meta-analyses or review studies because it is
easy to understand that original studies that show no ben-
efit or worse outcome when comparing a new technique
with usual care are less likely to be published [47,50]. Two
of the included studies [34,42] reported the effects of the
clinical pathway together with other hip/knee implant
standardisation programmes, and Dowsey et al. [32] used
pathways in association with a pre-admission informa-
tion seminar for the patients, which could have further
increased the statistical heterogeneity of the results. A ran-
dom effects analysis was performed in order to control
this heterogeneity and to increase the strength of the
observed findings [51-53].
The purpose of this study was to give a global vision of the
impact of hospital clinical pathways for JR. Some limita-
tions are raised from the nature of clinical pathways that
are complex interventions in which is difficult to deter-
mine which active components are the determinants of
the observed effects [20]. Only a few studies reported on
how the clinical pathways were implemented and used at
each site, so it is possible that some of the included studies
were evaluating different active components with differ-
ent effects. Moreover, from a health-service research per-
spective, hospitals are not static environments in which
Funnel plot analyses (hospitalisation costs) Figure 9
Funnel plot analyses (hospitalisation costs).
Review: Clinical pathway and total hip and knee arthroplasty
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clinical pathways are simply developed and applied but
the implementation of clinical pathways is often concur-
rent with other organisational initiatives that could inter-
act with pathways, enhancing or reducing their effects. It
should also be noted that the resources consumed for the
development and implementation of clinical pathways
were not included in the costs analysis of the studies
included in the meta-analysis and this could be a critical
issue when applying clinical pathways to low volume hos-
pitals [47].
Conclusion
Despite the possible limitations, the results of this meta-
analysis show that clinical pathways can significantly
improve the quality of care. It is not possible to conclude
that the implementation of clinical pathways is a cost-
effective process, because none of the included studies
analysed the cost of the development and implementa-
tion of the pathways. The active component of clinical
pathways remains unclear in most of the publications.
Based on this meta-analysis, the overall pathway literature
and the international experience of this research team, we
assume that pathways have an impact on the organisation
of care if the care process is structured in a standardised
way, teams critically analyse the actual organisation of the
process and the multidisciplinary team is highly involved
in the re-organisation. Further studies should focus on the
evaluation of pathways as complex interventions and are
needed to further help understand which mechanisms
within the clinical pathways can really improve the qual-
ity of care.
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